Lynn Morris
Lynn Morris
National Institute for Communicable Diseases
Verified email at
Cited by
Cited by
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
Q Abdool Karim, SS Abdool Karim, JA Frohlich, AC Grobler, C Baxter, ...
Science 329 (5996), 1168-1174, 2010
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
QA Karim, SSA Karim, JA Frohlich, AC Grobler, C Baxter, LE Mansoor, ...
Science (New York, NY) 329 (5996), 1168, 2010
SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma
CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ...
Nature medicine 27 (4), 622-625, 2021
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
M Pancera, T Zhou, A Druz, IS Georgiev, C Soto, J Gorman, J Huang, ...
Nature 514 (7523), 455-461, 2014
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies …
GD Tomaras, NL Yates, P Liu, L Qin, GG Fouda, LL Chavez, AC Decamp, ...
Journal of virology 82 (24), 12449-12463, 2008
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ...
Nature 509 (7498), 55-62, 2014
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection
ES Gray, MC Madiga, T Hermanus, PL Moore, CK Wibmer, NL Tumba, ...
Journal of virology 85 (10), 4828-4840, 2011
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
L Stamatatos, L Morris, DR Burton, JR Mascola
Nature medicine 15 (8), 866-870, 2009
Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa
Clinical Infectious Diseases 73 (7), e2005-e2015, 2021
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
M Bonsignori, KK Hwang, X Chen, CY Tsao, L Morris, E Gray, DJ Marshall, ...
Journal of virology 85 (19), 9998-10009, 2011
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
PL Moore, ET Crooks, L Porter, P Zhu, CS Cayanan, H Grise, P Corcoran, ...
Journal of virology 80 (5), 2515-2528, 2006
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
JM Binley, EA Lybarger, ET Crooks, MS Seaman, E Gray, KL Davis, ...
Journal of virology 82 (23), 11651-11668, 2008
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
ES Gray, PL Moore, IA Choge, JM Decker, F Bibollet-Ruche, H Li, ...
Journal of virology 81 (12), 6187-6196, 2007
Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired …
M Li, JF Salazar-Gonzalez, CA Derdeyn, L Morris, C Williamson, ...
Journal of virology 80 (23), 11776-11790, 2006
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), e112, 2005
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape
PL Moore, ES Gray, CK Wibmer, JN Bhiman, M Nonyane, DJ Sheward, ...
Nature medicine 18 (11), 1688-1692, 2012
Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ...
New England Journal of Medicine 384 (11), 1003-1014, 2021
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
A Trkola, TJ Ketas, KA Nagashima, L Zhao, T Cilliers, L Morris, JP Moore, ...
Journal of virology 75 (2), 579-588, 2001
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines
JR Mascola, P D'Souza, P Gilbert, BH Hahn, NL Haigwood, L Morris, ...
Journal of virology 79 (16), 10103-10107, 2005
The system can't perform the operation now. Try again later.
Articles 1–20